Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 691 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Corticosteroid Clear all

Conditions: Acromioclavicular Sprain
Interventions: Lidocaine injection, Corticosteroid Injection, Protein Rich Plasma(PRP) Injection; Drug
Lead sponsor: Brooke Army Medical Center; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 2
States / cities: San Antonio, Texas • Tacoma, Washington

Conditions: Asthma
Interventions: Fluticasone propionate 100mcg, Placebo, Vilanterol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 5 Years to 11 Years
Enrollment: 463 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 34
States / cities: Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 31 more

Conditions: Seasonal Allergic Rhinitis
Interventions: Bepotastine besilate formulation, Fluticasone propionate, Bepotastine besilate-fluticasone propionate, Placebo Comparator; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 606 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Irvine, California

Conditions: Adrenocortical Tumor
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 9,999 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2040
U.S. locations: 5
States / cities: Stanford, California • St. Petersburg, Florida • Dayton, Ohio + 2 more

Conditions: Atopic Dermatitis
Interventions: Tralokinumab + TCS, Placebo + TCS; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 6 Months to 11 Years
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 15
States / cities: Birmingham, Alabama • North Little Rock, Arkansas • Palo Alto, California + 11 more

Conditions: ENSAT Stage I Adrenal Cortex Carcinoma, ENSAT Stage II Adrenal Cortex Carcinoma, ENSAT Stage III Adrenal Cortex Carcinoma
Interventions: Cisplatin, Etoposide, Mitotane, Quality-of-Life Assessment; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2029
U.S. locations: 3
States / cities: Ann Arbor, Michigan • St Louis, Missouri • Houston, Texas

Conditions: Duchenne Muscular Dystrophy
Interventions: Pamrevlumab, Placebo, Corticosteroids; Drug
Lead sponsor: Kyntra Bio; Industry
Eligibility: 6 Years to 11 Years · Male only
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 27
States / cities: Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 24 more

Conditions: Full-thickness Rotator Cuff Tear, Rotator Cuff Tendinitis
Interventions: Ketorolac, Marcaine, Kenalog; Drug
Lead sponsor: Michael Khazzam; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Graft Vs Host Disease, Acute-graft-versus-host Disease, Chronic Graft-versus-host-disease
Interventions: Exercise, Attention control; Behavioral
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Solid Tumors
Interventions: Avelumab; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,756 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 53
States / cities: Goodyear, Arizona • Scottsdale, Arizona • Rogers, Arkansas + 45 more

Conditions: Asthma
Interventions: Ciclesonide (XRP1526); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 708 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Injection Fear, Injection Pain Prevention, Injection Complication
Interventions: Ethyl Chloride, Cold Saline Spray; Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Systemic Lupus Erythematosus
Interventions: Anifrolumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: Female only
Enrollment: 442 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: Pulmonary Sarcoidosis
Interventions: Efzofitimod 1.0 mg/kg or Placebo, Efzofitimod 3.0 mg/kg or Placebo, Efzofitimod 5.0 mg/kg or Placebo; Biological
Lead sponsor: aTyr Pharma, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 15
States / cities: Birmingham, Alabama • Northridge, California • Denver, Colorado + 11 more

Conditions: Adrenocortical Carcinoma (ACC), Recurrent Adrenocortical Carcinoma (ACC), Recurrent Abdominal Adrenocortical Carcinoma (ACC), Carcinoma, Adrenocortical, Carcinoma, Adrenal Cortical
Interventions: Surgical resection, Preoperative RT; Procedure · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2040
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Bone Diseases, Metabolic, Depression, Involutional, Osteoporosis
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: Not listed
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Bronchiolitis
Interventions: prednisolone or methylprednisolone, placebo; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 4 Weeks to 24 Months
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Adrenal Cortex Neoplasms
Interventions: XR9576 (Tariquidar); Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Kidney Transplantation, Renal Transplantation
Interventions: Alemtuzumab, MMF, Basiliximab, Short-term Tac, tacrolimus, Belatacept, methylprednisolone; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 3
States / cities: Birmingham, Alabama • San Francisco, California • Atlanta, Georgia

Conditions: Atopic Dermatitis
Interventions: Placebo, Upadacitinib, Topical corticosteroids (TCS); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 1,533 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 59
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 51 more

Conditions: Cancer
Interventions: entinostat; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 3
States / cities: Bethesda, Maryland

Conditions: Graft-versus-host Disease (GVHD)
Interventions: Ruxolitinib, Prednisone or methylprednisolone; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 12 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 38
States / cities: Tucson, Arizona • Duarte, California • La Jolla, California + 29 more

Conditions: Osteoarthritis
Interventions: triamcinolone acetonide, saline; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 2
States / cities: La Jolla, California

Conditions: Lumbosacral Radicular Pain
Interventions: SP-102, Placebo; Drug
Lead sponsor: Scilex Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 401 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 37
States / cities: Mobile, Alabama • Phoenix, Arizona • Tempe, Arizona + 30 more

Search by objective public record fields.

Platelet-rich Plasma, Corticosteroid, or Lidocaine for Acromioclavicular Joint Pain

Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children

Bepotastine Besilate-corticosteroid Nasal Spray Combination Compared to Placebo, Bepotastine Besilate Nasal Spray, and Corticosteroid Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis

International Pediatric Adrenocortical Tumor Registry

A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis

Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence

Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMD

Effectiveness of Corticosteroid vs Ketorolac Shoulder Injections

Impact of Exercise on the Complications of Corticosteroids in Patients With GVHD: the RESTART Trial

Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)

Efficacy of Ciclesonide vs Placebo Administered as Once Daily or Twice Daily in Patients Not Treated With Inhaled Corticosteroid.

Does Ethyl Chloride Spray Work?

Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users

Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis

Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma

Use of Bone Biopsy to Better Understand the Causes of Decreased Bone Mineral Density in Depression

Steroids Helping Albuterol Responders Exclusively

Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer

Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation

A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)

Using Ultrasound to Predict Response to Intraarticular Corticosteroids in Knee Osteoarthritis

Corticosteroid Lumbar Epidural Analgesia for Radiculopathy